Austin TR, McHugh CP, Brody JA, et al. Proteomics and Population Biology in the Cardiovascular Health Study (CHS): design of a study with mentored access and active data sharing. Eur J Epidemiol. 2022;37(7):755-765. doi:10.1007/s10654-022-00888-z
Proteomics Platform
Sellar RS, Sperling AS, SÅ‚abicki M, et al. Degradation of GSPT1 causes TP53-independent cell death in leukemia whilst sparing normal hematopoietic stem cells. J Clin Invest. 2022. doi:10.1172/JCI153514
Hallacli E, Kayatekin C, Nazeen S, et al. The Parkinson’s disease protein alpha-synuclein is a modulator of processing bodies and mRNA stability. Cell. 2022;185(12):2035-2056.e33. doi:10.1016/j.cell.2022.05.008
Fang L, Ford-Roshon D, Russo M, et al. RNF43 G659fs is an oncogenic colorectal cancer mutation and sensitizes tumor cells to PI3K/mTOR inhibition. Nat Commun. 2022;13(1):3181. doi:10.1038/s41467-022-30794-7
Fass DM, Lewis MC, Ahmad R, et al. Brain-specific deletion of GIT1 impairs cognition and alters phosphorylation of synaptic protein networks implicated in schizophrenia susceptibility. Mol Psychiatry. 2022. doi:10.1038/s41380-022-01557-z
Oliveira G, Stromhaug K, Cieri N, et al. Landscape of helper and regulatory antitumour CD4 T cells in melanoma. Nature. 2022;605(7910):532-538. doi:10.1038/s41586-022-04682-5
Wu CH, Tatavarty V, Beltran PMJ, et al. A bidirectional switch in the Shank3 phosphorylation state biases synapses toward up- or downscaling. Elife. 2022;11. doi:10.7554/eLife.74277
Mani DR, Krug K, Zhang B, et al. Cancer proteogenomics: current impact and future prospects. Nat Rev Cancer. 2022. doi:10.1038/s41568-022-00446-5
Schaefer EJ, Wang HC, Karp HQ, et al. BCOR and BCORL1 Mutations Drive Epigenetic Reprogramming and Oncogenic Signaling by Unlinking PRC1.1 from Target Genes. Blood Cancer Discov. 2022;3(2):116-135. doi:10.1158/2643-3230.BCD-21-0115
Khadka P, Reitman ZJ, Lu S, et al. PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. Nat Commun. 2022;13(1):604. doi:10.1038/s41467-022-28198-8